The Diocheck SARS-CoV-2 Visual Immune Response Indicator provides a simple, universal way to continually monitor a person’s immune response status to COVID-19 over an extended period of time … Details
University of Cambridge receives Multi-million Dollar Funding for Clinical Trial using PharmaJet’s Needle-free System to Deliver Vaccine to Prevent COVID-19GOLDEN, Colo. — October 27, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible. Details
International Pharmaceutical Development Consortium to partner with PharmaJet for delivery of COVID-19 DNA Vaccine, GX-19GOLDEN, Colo. — September 15, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea. The consortium also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology. Details
PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology
GOLDEN, Colo. — May 19, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.Details
GOLDEN, Colo. — April 28, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the appointment of Chris Cappello to President and Chief Executive Officer. Chris replaces Ron Lowy, who was appointed Executive Chairman of the board.
Ron Lowy, Executive Chairman, PharmaJet Inc. said, “ In the 10 years that Chris has worked for PharmaJet he has shown the ability to lead the organization and expand on our important collaborations with groups such as the US federal government, the World Health Organization, multiple pharmaceutical partnerships…Details